Physician profile
Patrick Williams
NPI 1598728727
$5,403.71
in general payments reported to CMS, 2019-2025
56 companies · $2,586 in 2025
The $2,586 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $258 · 2020: $90.39 · 2021: $61.45 · 2022: $22.17 · 2023: $925 · 2024: $1,460 · 2025: $2,586.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,834 · Education: $138.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,833.63 |
| Education | $137.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $493.34 | 2023-2025 | Keytruda, Lynparza, Welireg |
| Novartis Pharmaceuticals Corporation | $490.39 | 2023-2025 | Piqray, Kisqali |
| Astrazeneca Pharmaceuticals Lp | $464.98 | 2019-2025 | Lynparza, Tagrisso, Imfinzi |
| Pfizer INC. | $339.60 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $304.94 | 2019-2025 | Opdivo, Opdualag, Breyanzi |
| Abbvie INC. | $294.84 | 2023-2025 | Venclexta |
| Astellas Pharma US INC | $226.41 | 2019-2025 | Xtandi, Vyloy |
| Celgene Corporation | $221.03 | 2023-2025 | Reblozyl |
| Genentech USA, INC. | $193.74 | 2024-2025 | Itovebi, Polivy, Tecentriq |
| Gilead Sciences, INC. | $163.86 | 2021-2025 | Trodelvy |
| Genzyme Corporation | $156.80 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $154.91 | 2023-2025 | Libtayo |
| Jazz Pharmaceuticals INC. | $146.68 | 2023-2025 | |
| Janssen Biotech, INC. | $135.44 | 2024-2025 | Tecvayli, Darzalex, Rybrevant |
| Genmab U.S., INC. | $108.97 | 2023-2025 | Tivdak, Epkinly |
Show all 56 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rigel Pharmaceuticals, INC. | $97.20 | 2023 | Rezlidhia, Tavalisse |
| Daiichi Sankyo INC. | $81.89 | 2019-2025 | Enhertu, Datroway |
| Eisai INC. | $77.16 | 2020-2025 | |
| Puma Biotechnology, INC. | $68.50 | 2024 | |
| Array Biopharma INC | $67.55 | 2025 | Braftovi, Mektovi, Tukysa |
| Karyopharm Therapeutics INC. | $65.39 | 2024-2025 | Xpovio |
| Emd Serono, INC. | $64.19 | 2019-2025 | |
| Pharmaessentia USA Corporation | $63.27 | 2024-2025 | Besremi |
| Caris Mpi, INC. | $62.82 | 2025 | Mi Cancer Seek |
| Legend Biotech USA INC. | $62.76 | 2025 | Carvykti |
| Lilly USA, LLC | $61.01 | 2024-2025 | Verzenio, Jaypirca, Retevmo |
| Sumitomo Pharma America, INC. | $55.11 | 2025 | Orgovyx |
| Blueprint Medicines Corporation | $49.48 | 2024-2025 | Ayvakit |
| Adc Therapeutics America, INC. | $48.61 | 2025 | |
| Sobi, INC | $41.58 | 2024-2025 | |
| Kyowa Kirin, INC. | $41.07 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $39.81 | 2025 | Onivyde |
| Mirati Therapeutics, INC. | $37.94 | 2024 | Krazati |
| Iovance Biotherapeutics, INC. | $33.67 | 2025 | Amtagvi |
| Portola Pharmaceuticals, LLC | $22.81 | 2019 | |
| Beigene USA, INC. | $22.76 | 2024 | Brukinsa |
| Deciphera Pharmaceuticals INC. | $21.62 | 2025 | Romvimza, Qinlock |
| Accord Healthcare, INC. | $21.30 | 2025 | |
| Aveo Pharmaceuticals, INC. | $20.00 | 2024 | |
| Alexion Pharmaceuticals, INC. | $19.61 | 2023 | Ultomiris |
| Fennec Pharmaceuticals, INC. | $19.17 | 2024 | Pedmark |
| Takeda Pharmaceuticals U.S.A., INC. | $18.89 | 2023 | Fruzaqla |
| Pharmacosmos Therapeutics INC. | $18.86 | 2023 | Monoferric |
| Incyte Corporation | $18.12 | 2023 | Pemazyre, Monjuvi, Jakafi |
| Secura Bio, INC. | $18.00 | 2024 | Copiktra |
| Servier Pharmaceuticals LLC | $17.74 | 2023 | |
| Immunocore Limited | $17.18 | 2025 | Kimmtrak |
| Coherus Oncology, INC. | $17.12 | 2025 | Loqtorzi |
| Syndax Pharmaceuticals, INC. | $16.43 | 2025 | |
| Novocure INC. | $16.00 | 2025 | Optune Lua (Novottf-200t) |
| Alnylam Pharmaceuticals INC. | $15.52 | 2025 | Givlaari |
| Glaxosmithkline, LLC. | $15.25 | 2023 | Jemperli, Zejula |
| Adaptive Biotechnologies Corporation | $13.62 | 2024 | Clonoseq |
| Tempus Ai, INC | $13.50 | 2024 | |
| Springworks Therapeutics, INC. | $13.43 | 2024 | Ogsiveo |
| Flowonix Medical Incorporated | $11.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.